ClickCease

Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression.

Siegel JS, Palanca BJA, Ances BM, Kharasch ED, Schweiger JA, Yingling MD, Snyder AZ, Nicol GE, Lenze EJ, Farber NB. Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression. Psychopharmacology (Berl). 2021 Apr;238(4):1157-1169. doi: 10.1007/s00213-021-05762-6. Epub 2021 Jan 22. PMID: 33483802; PMCID: PMC7969576.   Highlights: ·         In this open-label, proof-of-principle study, […]

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.

Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, Van Nueten L. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. Am J Psychiatry. 2016 Aug 1;173(8):816-26. doi: […]

At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-labeled effectiveness trial.

Thomas D. Hull, Matteo Malgaroli, Adam Gazzaley, Teddy J. Akiki, Alok Madan, Leonardo Vando, Kristin Arden, Jack Swain, Madeline Klotz, Casey Paleos, At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial, Journal of Affective Disorders, Volume 314, 2022, Pages […]

Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy.

Dore J, Turnipseed B, Dwyer S, Turnipseed A, Andries J, Ascani G, Monnette C, Huidekoper A, Strauss N, Wolfson P. Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy. J Psychoactive Drugs. 2019 Apr-Jun;51(2):189-198. doi: 10.1080/02791072.2019.1587556. Epub 2019 Mar 27. PMID: 30917760. Highlights: Our findings suggest […]

Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression.

Bipolar-Depressive-Episoide

Lara DR, Bisol LW, Munari LR. Antidepressant, mood stabilizing, and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. Int J Neuropsychopharmacol. 2013 Oct;16(9):2111-7. doi: 10.1017/S1461145713000485. Epub 2013 May 20. PMID: 23683309. Highlights: According to patients’ reports, VLDS [very low dose sublingual] ketamine produced rapid, clear, and sustained effects, improving […]

Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.

Anand, A et al. (2023).  Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.  N Engl J Med 2023;388:2315-25. DOI: 10.1056/NEJMoa2302399  Highlights: A total of 55.4% of the patients in the ketamine group and 41.2% of those in the ECT group had a response. Patients with treatment-resistant major depression without psychosis were recruited and assigned in […]

Ketamine normalizes subgenual cingulate cortex hyper-activity in depression.

Morris, L. S., Costi, S., Tan, A., Stern, E. R., Charney, D. S., & Murrough, J. W. (2020). Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. Neuropsychopharmacology, 45(6), 975–981.  Highlights: There was a significant improvement in MDD symptoms following a single-dose intravenous ketamine. Following a 40-minute infusion of ketamine at a dose of 0.5mg/kg, patients […]

Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression.

Chen, M. H., Wu, H. J., Li, C. T., Lin, W. C., Tsai, S. J., Hong, C. J., Tu, P. C., Bai, Y. M., Mao, W. C., & Su, T. P. (2021). Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. Human Psychopharmacology: Clinical and Experimental, […]

Treatment resistant depression at a glance with traditional, first line antidepressant treatments, as well as a review of the evidence behind esketamine, psilocybin and pramipexole.

Kverno KS, Mangano E. Treatment-Resistant Depression: Approaches to Treatment. J Psychosoc Nurs Ment Health Serv. 2021 Sep;59(9):7-11. doi: 10.3928/02793695-20210816-01. Epub 2021 Sep 1. PMID: 34459676. Highlights: Approximately 30% of people treated for a major depressive episode will not achieve remission after two or more treatment trials of first-line antidepressants and are considered to have treatment-resistant […]

Ketamine and the Future of Rapid-Acting Antidepressants.

Lace M. Riggs and Todd D. Gould.  Ketamine and the Future of Rapid-Acting Antidepressants.  Annual Review of Clinical Psychology 2021 17:1, 207-231   Highlights: The therapeutic onset of traditional antidepressants is delayed by several weeks and many depressed patients fail to respond to treatment altogether. In contrast, subanesthetic ketamine can rapidly alleviate symptoms of depression […]